R	ecei	ot d	late:	08/1	8/	(20)	06
	~ ~ ~ I	~~~	1 G-16 & No. 1	V V/ 1	21	- V	~ ~

eceipt date: 08/18/20	06 Paperwork Redu	uction Act of 1995	no postanta	10/590 Recupilibili	210590265 - GAU: 1626 Comparable to Form PTO/SB/08A (08-03) Approved for use through 97/31/2006. OMB 0651-0031 and Trademar AGFI COLUMN ATTENDED TO COMMERCE of irrformation unless if displace valid OMB control number.
			60 m	Application Number	Unassigned
Substitute for form 1449A/PTO				Filing Date	08/18/2006
INFORMATIO	N DISCL	OSURE		First Named Inventor	Astrid Netz et al.
STATEMENT 1	BY APPL	ICANT		Group Art Unit	Unknown
(Use as many sh	ieets as necess	sary)		Examiner Name	Unknown
Shoot		- 6		Attornov Dookst No	A DD 1001 0D022401 IS .

U.S. PATENT DOCUMENTS								
Examiner	Cite	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear			
Initials*	No. <sup>1</sup>	Number Kind Code <sup>2</sup> (if known)						
/FTP/		US- 4,560,690 A	12/24/1985	Reiter, Lawrence Alan				

		FOREIGN P.	ATENT DOCUMENT	rs .	
xamiles Initials'	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		JP 09 040671 A	02/10/1997	Fujisawa Pharmaceutical Co., Ltd.	
		39,08 337579 A	12/24/1996	Fujisawa Pharmaceutica Co. Ltd.	
		JP 08 245621	09/24/1996	Fujisawa Prarmaceutical Co., Ltd	
		WO 96/05187 A1	02/22/1996	Fujisawa Pharmaceutical Co., Ltd.	
		WO 95/18126 A1	07/06/1903	Fujisawa Pharmaceutical Co., Ltd.	
		EP 0 545 376 A1	06/09/1993	Fujisawa Pharmaceutical Co., Ltd.	
		WO 92/16526 A1	10/01/1992	Fujisawa Pharmaceutical Co., L	į į
		EP 0 259 985 A1	03/09/1988	Pfizer Inc., USA	
		19 59 036674 A	02/28/1984	Yamanouchi Pharmaceutical Co., Ltd.	
		WO 02/16318 A	02/28/2002	Pacific Corporation	
	A STATE OF THE STA	WO 99/20599 A	04/29/1999	Cambridge Neuroscience	
No.	The state of the s	WO 02/36544 A	05/10/2002	Tokuyama Corporation	
STATE OF THE PARTY		GB 1 031 165 A	05/25/1966	The Wellcome Foundation Ltd.	
aminer Si	anature	/Fiona T. Powers/		Date Considered	08/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.
<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 08/18/2006

1890 Rec'd PCT/P10 18 AUG 20 proved for use through 0731/2006 OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

As a filled a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO			Application Number	u of information unless it displays a valid OMB control number Unassigned	
Substitute for form 1449A/P1O				Filing Date	08/18/2006
INFORMATIO				First Named Inventor	Astrid Netz et al.
STATEMENT	BY APPI	ICANT		Group Art Unit	Unknown
(Use os many si	neets as neces	sary)		Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket No.	ABB10010P02240US

San	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.						
	KASURA YOUSUKE ET AL Anti-Helicobocter pylori Agents. 5. 2-(Substituted guonidino)-4-orylthiazoles and Aryloxazole Analogues Journal of Medicinal Chemistry, Vol. 45, No. 1 (2002) pp. 143-150.					
	KATSURA YOUS KE ET AL Anti-Helicobocter pylori Agents. 4. 2-(Substituted guonidino)-4-phenylthiozoles and Some Structurally Rigid Derivatives Journal of Medicinal Chemistry Vol. 43, No. 17 (2000) pp. 3315-21					
	HOGBERG MARITA ET AL Bioisosteric modification of PETT-HIV-1 RT-inhibitors: synthesis and biological evaluation Bioorganic & Medicinal Chemistry Letter Vol. 10, No. 3 (2000) pp. 265-68					
	KATSURA YOUSUKE ET AL Anti-Helicobacter pylori agents. 3. 2-'(Arylalkyl)gymidinol-4-furylthiozoles Journal of Medicinal Chemistry Vol 42, No. 15 (1999) pp. 2920-26					
	GUPTA S ET AL Superpendentic Index: A novel topological descriptor for predicting biological activity Journal of Chemical Information and Computer Sciences Vol 39, No. 2 (1999) pp. 278-27					
	KATSURA YOSUKE ET AL Preparation of furylthiazeles as ulcer inhibitors Doc. No. XO002341494 CAPLUS Chemical Abstracts Service Columbus, OH Database Accession No. 1997:195723					
	KATSURA YOSUKE ET AL Preparation of guanidinothiazole derivatives as Instamine H2 antagonists Doc. No. XP002341495 CAPLUS Chemical Abstracts Service Columbus, OH Database Accession No. 1992:140933					
	KAWANISHI YASUYUKUET AL Synthesis and biological evaluation of a new reversely linked type of dual histamine H2 and gastrin receptor antagodist Doc. No. XP002341496 CAPLUS Chemical Abstracts Service Columbus, OH Database Accession No. 1997:81087					
	Chemical & Pharmaceutical Bulletin Vol. 45, No. 1 (1997) pp. 116-124					
	Preparation of 4-thienylthiazole derivatives as antiulcer and antibacterial agents Doc. No. XP002341497 CAPLUS Chemical Abstracts Service Columbus, OH Database Accession No. 1997:42					
	GOEL ANSHU ET AL Structure-Activity Study on Antiulcer Agents Using Wiener's Topological Index and Molecular Connectivity Index Journal of Chemical Information and Computer Sciences Vol. 35, No. 3 (1995) pp. 504-09					
xaminer Signature	/Fiona T. Powers/ 08/13/2010					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.